• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

IV ferric carboxymaltose reduces risk of heart failure hospitalizations in patients with iron-deficiency and acute heart failure

byVineeth BhogadiandTeddy Guo
December 24, 2020
in Cardiology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%.

2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Iron deficiency is a common comorbidity in patients with heart failure and is associated with increased risk of hospitalization and mortality. IV ferric carboxymaltose has previously been shown to improve symptoms and was associated with a lower rate of hospitalizations and cardiovascular mortality in patients with chronic heart failure. However, it is unclear if IV ferric carboxymaltose could have beneficial effects on patients admitted for acute heart failure where risk of mortality and re-hospitalization remains high. This randomized controlled trial included adults hospitalized for acute heart failure with concomitant iron deficiency. Patients were randomized at time of discharge to receive either IV ferric carboxymaltose or placebo for up to 24 weeks. Results suggested that treatment with ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency, left ventricular ejection fraction less than 50% and who had stabilized following admission with acute heart failure. Treatment with ferric carboxymaltose was generally safe but had no significant effect on the overall risk of cardiovascular death. Notably, the results of the trial may have been significantly impacted by the COVID-19 pandemic with regard to data collection and follow-up with a pre-COVID-19 sensitivity analysis demonstrating a significant benefit of ferric carboxymaltose on combined total heart failure hospitalizations and cardiovascular mortality. Additionally, the study design did not include patients assigned to receive oral iron supplementation and therefore it is unclear if the benefit seen extends to this group.

Click to read the study in The Lancet

Relevant Reading: Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

In-Depth [randomized controlled trial]: This randomized, double-blind, controlled trial conducted in 121 centers across Europe, South America and Singapore included adults aged ≥18 years hospitalized for acute heart failure with left ventricular ejection fraction less than 50%, and concomitant iron deficiency defined as serum ferritin less than 100 ng/mL or 100-299 ng/mL with transferrin saturation of less than 20%. Patients were randomly assigned to receive either IV ferric carboxymaltose or placebo with the first dose of treatment administered before discharge from hospital. Additional doses were given at weeks 6, 12, and 24 if iron deficiency persisted. The primary endpoint was a composite of total heart failure hospitalizations and cardiovascular mortality up to 52 weeks of follow-up.

RELATED REPORTS

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

A total of 1132 patients met the inclusion criteria between March 2017 and July 2019 and were assigned to receive either IV ferric carboxymaltose or placebo. A total of 293 primary events (57.2 per 100 patient years) occurred in the ferric carboxymaltose group compared to 372 (72.5 per 100 patient years) in the placebo group (rate ratio [RR] 0.79, 95% CI 0.62 to 1.01; p=0.059) falling short of the conventional 5% statistical significance. However, in the pre-COVID-19 sensitivity analysis, 274 primary events occurred in 228 patients in the ferric carboxymaltose group compared to 363 events in 550 patients in the placebo group (RR 0.75, 95% CI 0.59 to 0.96; p=0.024). Significantly fewer heart failure hospitalizations occurred in the ferric carboxymaltose group (217) compared to the 294 in the placebo group (RR 0.74, 95% CI 0.58 to 0.94; p=0.013). There was no difference in cardiovascular death between the two groups (14% in both the ferric carboxymaltose group and placebo group; Hazard Ratio [HR] 0.96, 95% CI 0.70 to 1.32; p=0.81).

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute heart failurecongestive heart failureferric carboxymaltoseheart failureiron deficiency
Previous Post

#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients

Next Post

COVID-19 susceptibility may be increased in patients with hematological malignancies compared to solid organ tumours

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

June 9, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Next Post
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

COVID-19 susceptibility may be increased in patients with hematological malignancies compared to solid organ tumours

Hydroxychloroquine not beneficial for early, mild COVID-19

Special Report: Vaccines in Development Part 5: Potential emerging vaccine candidates and other considerations

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.